Crossmark Global Holdings Inc. Boosts Stake in DaVita Inc. (NYSE:DVA)

Crossmark Global Holdings Inc. boosted its stake in shares of DaVita Inc. (NYSE:DVA) by 36.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,827 shares of the company’s stock after buying an additional 6,896 shares during the period. Crossmark Global Holdings Inc.’s holdings in DaVita were worth $4,234,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Transcendent Capital Group LLC acquired a new position in shares of DaVita during the third quarter worth $25,000. Blue Trust Inc. increased its position in shares of DaVita by 58.6% during the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after purchasing an additional 78 shares in the last quarter. Family Firm Inc. acquired a new position in shares of DaVita in the 2nd quarter valued at $43,000. Versant Capital Management Inc increased its position in shares of DaVita by 90.6% in the 2nd quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after acquiring an additional 155 shares during the period. Finally, Friedenthal Financial acquired a new position in shares of DaVita in the 2nd quarter valued at $48,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Joel Ackerman sold 64,029 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the transaction, the chief financial officer now owns 111,481 shares in the company, valued at $17,286,243.86. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, COO Michael David Staffieri sold 9,539 shares of the stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the transaction, the chief operating officer now owns 241,945 shares in the company, valued at $36,299,008.35. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Joel Ackerman sold 64,029 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total value of $9,928,336.74. Following the transaction, the chief financial officer now owns 111,481 shares in the company, valued at $17,286,243.86. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 165,625 shares of company stock worth $26,238,297. Corporate insiders own 2.00% of the company’s stock.

DaVita Trading Up 3.2 %

DaVita stock opened at $154.48 on Tuesday. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. DaVita Inc. has a 12 month low of $84.64 and a 12 month high of $168.50. The stock’s 50 day simple moving average is $157.22 and its two-hundred day simple moving average is $147.05. The firm has a market cap of $12.67 billion, a PE ratio of 16.66, a P/E/G ratio of 0.84 and a beta of 0.89.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. During the same quarter in the prior year, the company posted $2.85 EPS. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. Analysts anticipate that DaVita Inc. will post 9.71 earnings per share for the current year.

Analyst Upgrades and Downgrades

DVA has been the topic of several research reports. Truist Financial upped their target price on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. TD Cowen upped their target price on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. UBS Group upped their target price on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Barclays upped their target price on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Finally, Bank of America lifted their price objective on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $161.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.